Changed date for announcement of Financiel Results


Release No 4/2010			
Revised Financial Calendar 2010                                                 

Changed date for Release of 2009 Financial Results                              
					                                                                           
Copenhagen and Oslo, March 26th, 2010                                           
Affitech A/S has changed the date for the release of its full year financial    
results and Annual Report from March 26th to March 31st, 2010.                  


Affitech A/S's updated financial calendar is as follows:                        

March 31st 2010:		Financial Results for 2009                                    
April 29th 2010:		Annual General Meeting                                        
May 19th 2010:		Interim financial report for 1st quarter 2010                   
August 26th 2010:		Interim financial report for 2nd quarter 2010                
November 18th 2010:	Interim financial report for 3rd quarter 2010               
		                                                                              

--------------------------------------------------------------------------------
| For more information please contact:                                         |
--------------------------------------------------------------------------------
|                                                                              |
| Affitech A/S:                                                                |
|                                                                              |
| Randi Krogsgaard                                                             |
| Tel # +45 2048 8384                                                          |
--------------------------------------------------------------------------------

About Affitech                                                                  
Affitech AS is a publically traded (NASDAQ OMX Copenhagen) therapeutic antibody 
company headquartered in Copenhagen, Denmark with R&D facilities in Oslo,       
Norway. The company utilizes a range of proprietary antibody technologies for   
the discovery of therapeutic antibodies for application in oncology,            
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is  
Affitech A/Ss premier technology platform for the isolation of lead antibodies  
to cell surface targets. Several of the Company's proprietary drug candidates   
were generated by CBAS™. Further information is available at www.affitech.com.
GlobeNewswire